So, you know how biotech stocks can sometimes move on news that sounds like regulatory alphabet soup? Well, Praxis Precision Medicines Inc. (PRAX) is having one of those days. The company's shares jumped on Tuesday after it announced the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) for a drug called ulixacaltamide HCl. This is a treatment for essential tremor, which is a common neurological disorder that causes involuntary shaking, usually in the hands or head.
Think of it like this: the FDA just opened the mail, saw Praxis's application, and said, "Okay, this looks complete enough for us to start reviewing." That's the "acceptance" part. They've even penciled in a target date to make a decision: January 29, 2027. It's a big step because it gets the formal clock ticking toward a potential approval. The drug also has a special status called Breakthrough Therapy Designation, which is basically the FDA's way of saying, "This looks promising for a serious condition, so we'll try to review it faster." For patients with essential tremor, it could be a much-needed new therapy.
What's in the Application? Solid Trial Data
The application isn't just a stack of hopeful paperwork. It's backed by data from something called the Essential3 Phase 3 program, which was two big studies run at the same time in adults with essential tremor. In the first study, patients on the drug showed a statistically significant and clinically meaningful improvement on a scale that measures how the tremor affects daily activities. In the second study, 55% of patients taking ulixacaltamide maintained their response after eight weeks, compared to only 33% of those on a placebo. That's the kind of data that makes regulators pay attention.
But Wait, There's More Good News
This isn't the only thing Praxis has going on. Just last week, the company shared results from a trial for a different drug called elsunersen. This one is for a rare and severe form of genetic epilepsy in kids. The results were pretty striking: elsunersen showed a placebo-adjusted seizure reduction of 77%. To put a finer point on it, 71% of kids treated with the drug saw their seizures cut by more than half, and over half of the patients experienced at least a 28-day period with no seizures at all. The efficacy even held up for up to a year in a follow-on part of the study. So, while the essential tremor news is driving today's move, the company's pipeline has more than one promising candidate.
The Stock's Wild Ride and What Analysts Think
Now, let's talk about the stock itself, because its chart looks like a rocket launch. Praxis is trading right near its 52-week high of $356.00. It's above its key short-term moving averages, which technical traders see as a bullish sign. Its Relative Strength Index is sitting in a neutral zone, suggesting it might not be overbought yet and could have room to run. Over the past 12 months, the stock is up an eye-watering 1,038.45%. Yes, you read that right—over a thousand percent.
Analysts are largely on board with the story. The consensus rating is a "Buy," with an average price target of $588.60. Just in the first two weeks of April, a few firms reiterated their bullish stances: Needham maintained a Buy rating and a $510 target, HC Wainwright & Co. kept its Buy and a whopping $1,245 target, and BTIG maintained its Buy with an $843 target. Clearly, there's optimism about what the FDA decision next year could mean.
As of publication on Tuesday, Praxis Precision Medicines shares were up 7.15% at $339.67. The stock is a high-flyer with major news on the horizon, and today's FDA acceptance is a key checkpoint on that path.
.jpeg)
